Get started
Author

Eva Lengyelova

Observed name: E. Lengyelova
OpenAlex ID: A5070907444
A Novel Theranostic Trial Design Using 64Cu/67Cu with Fully 3D Pre-Treatment Dosimetry
2019 · Dale L. Bailey, Geoffrey Schembri, et al. · Journal of Nuclear Medicine · 10
64Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer.
2023 · Eva Lengyelova, Veronica Wong, et al. · Journal of Clinical Oncology · 6
COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy.
2024 · Luke Nordquist, Eva Lengyelova, et al. · Journal of Clinical Oncology · 4
COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer.
2024 · Luke T. Nordquist, Eva Lengyelova, et al. · Journal of Clinical Oncology · 3
PDF
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.
2024 · Geoffrey Johnson, Eva Lengyelova, et al. · Journal of Clinical Oncology · 2
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.
2024 · Geoffrey Johnson, Eva Lengyelova, et al. · Journal of Clinical Oncology · 2
SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.
2024 · Luke T. Nordquist, Eva Lengyelova, et al. · Journal of Clinical Oncology · 2
COBRA: Assessment of the efficacy of 64 Cu-SAR-bisPSMA using histopathology and standard of care imaging as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy.
2025 · Luke Nordquist, Eva Lengyelova, et al. · Journal of Clinical Oncology · 1
PDF
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67 Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.
2025 · Geoffrey Bates Johnson, Eva Lengyelova, et al. · Journal of Clinical Oncology · 1
PDF
COBRA: Assessment of the efficacy of 64 Cu-SAR-bisPSMA using histopathology as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy.
2025 · Luke Nordquist, Eva Lengyelova, et al. · Journal of Clinical Oncology · 1
CLARIFY: Positron emission tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy (a phase 3 diagnostic study).
2024 · Michael A. Gorin, Eva Lengyelova, et al. · Journal of Clinical Oncology · 1
Positron emission tomography of patients with confirmed prostate cancer using 64Cu-SAR-bisPSMA.
2023 · Louise Emmett, Veronica Wong, et al. · Journal of Clinical Oncology · 1
PDF
Optimization of Administered Activity for 64Cu-SAR-bisPSMA PET Imaging in Primary Prostate Cancer: Results from a Phase I Retrospective Study (PROPELLER Sub-study)
2026 · Eva Lengyelova, Manisha Patel, et al. · World Journal of Nuclear Medicine
PDF
AMPLIFY: A phase 3 study of 64 Cu-SAR-bisPSMA positron emission tomography in participants with biochemical recurrence of prostate cancer.
2026 · Luke Nordquist, Eva Lengyelova, et al. · Journal of Clinical Oncology
DISCO update: Diagnostic performance of 64 Cu-SARTATE compared to 68 Ga-DOTATATE in patients with known or suspected neuroendocrine tumors.
2026 · Eva Lengyelova, Grace Kong, et al. · Journal of Clinical Oncology
CLARIFY Phase 3 Trial: Positron Emission Tomography using 64Cu-SAR-bisPSMA in Patients with High-Risk Prostate Cancer Prior to Radical Prostatectomy
2026 · M. Gorin, E. Lengyelova, et al. · International Journal of Radiation Oncology*Biology*Physics
AMPLIFY: A Phase 3 Study of 64Cu-SAR-bisPSMA Positron Emission Tomography in Participants with Biochemical Recurrence of Prostate Cancer
2026 · N. Shore, E. Lengyelova, et al. · International Journal of Radiation Oncology*Biology*Physics
DISCO: Safety, Tolerability and Diagnostic performance of 64Cu-SARTATE compared to 68Ga-DOTATATE in patients with known or suspected neuroendocrine tumors
2026 · Eva Lengyelova, Nimit Singhal, et al. · Endocrine Abstracts
AMPLIFY: A phase 3 study of 64 Cu-SAR-bisPSMA positron emission tomography in participants with biochemical recurrence of prostate cancer.
2026 · Neal D. Shore, Eva Lengyelova, et al. · Journal of Clinical Oncology
DISCO: Diagnostic performance of 64 Cu-SARTATE compared to 68 Ga-DOTATATE in patients with known or suspected neuroendocrine tumors with focus on liver findings.
2026 · Eva Lengyelova, Grace Kong, et al. · Journal of Clinical Oncology
PDF
Mp13-01 Cobra: Assessment of 64 Cu-sar-bispsma and Standard of Care Prostate-specific Membrane Antigen Positron Emission Tomography in Patients With Biochemical Recurrence of Prostate Cancer Following Definitive Therapy
2025 · Luke Nordquist, Eva Lengyelova, et al. · The Journal of Urology
CLARIFY: Positron emission tomography using 64 Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy—A phase 3 diagnostic performance study.
2025 · Michael A. Gorin, Eva Lengyelova, et al. · Journal of Clinical Oncology
PDF
Works count: 22
Citation count: 34
H-index: 3
I10-index: 1
Year
Topic
Type